Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ANRO Alto Neuroscience Inc.
- Stocks
- Healthcare
- NYSE: ANRO
Price (delayed)
$2.35
Market cap
$63.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.34
Enterprise value
-$72.07M
We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Building on more than a decade of
Highlights
The EPS has soared by 73% year-on-year and by 6% since the previous quarter
ANRO's quick ratio is up by 32% since the previous quarter but it is down by 14% year-on-year
The debt has surged by 157% year-on-year and by 59% since the previous quarter
The company's net income fell by 49% YoY and by 2.9% QoQ
Key stats
What are the main financial stats of ANRO
Market
Valuations
Earnings
Shares outstanding
27.07M
Market cap
$63.62M
Enterprise value
-$72.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.46
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$69.9M
Net income
-$63.18M
EBIT
-$61.56M
EBITDA
-$60.53M
Free cash flow
-$54.87M
Per share
Balance sheet
Liquidity
EPS
-$2.34
EPS diluted
-$2.34
Free cash flow per share
-$2.03
Book value per share
$5.14
Revenue per share
$0
TBVPS
$6.36
Total assets
$171.92M
Total liabilities
$32.82M
Debt
$25.56M
Equity
$139.1M
Working capital
$156.27M
Debt to equity
0.18
Current ratio
22.53
Quick ratio
22.22
Net debt/EBITDA
2.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-34.2%
Return on equity
-39.8%
Return on invested capital
-415.5%
Return on capital employed
-37.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANRO stock price
How has the Alto Neuroscience stock price performed over time
Intraday
2.17%
1 week
2.17%
1 month
-10.65%
1 year
-79.78%
YTD
-44.44%
QTD
6.82%
Financial performance
How have Alto Neuroscience's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$69.9M
Net income
-$63.18M
Gross margin
N/A
Net margin
N/A
Alto Neuroscience's operating income has shrunk by 55% YoY
The company's net income fell by 49% YoY and by 2.9% QoQ
Price vs fundamentals
How does ANRO's price correlate with its fundamentals
Growth
What is Alto Neuroscience's growth rate over time
Valuation
What is Alto Neuroscience stock price valuation
P/E
N/A
P/B
0.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 73% year-on-year and by 6% since the previous quarter
The price to book (P/B) is 62% less than the last 4 quarters average of 1.2
ANRO's equity is down by 28% YoY and by 8% QoQ
Efficiency
How efficient is Alto Neuroscience business performance
The ROE has shrunk by 81% YoY and by 12% QoQ
The return on assets has dropped by 69% year-on-year and by 8% since the previous quarter
Alto Neuroscience's ROIC has increased by 39% YoY and by 37% from the previous quarter
Dividends
What is ANRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANRO.
Financial health
How did Alto Neuroscience financials performed over time
The total liabilities has soared by 95% YoY and by 26% QoQ
ANRO's current ratio is up by 33% since the previous quarter but it is down by 13% year-on-year
The debt is 82% smaller than the equity
The debt has surged by 157% year-on-year and by 59% since the previous quarter
ANRO's debt to equity has soared by 64% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.